FDA to Release Long-Awaited Guidance on CMO Agreements, Biosimilars in 2013 04-Feb-2013 By Zachary Brennan Highly sought-after guidance on quality agreements for contract manufacturing organizations (CMOs) and biosimilar developers is expected in 2013, according to a list of future guidance documents released by the US Food and Drug Administration (FDA).
